Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 19, 2011

Primary Completion Date

April 30, 2018

Study Completion Date

April 9, 2018

Conditions
Metastatic Breast CancerCarcinomatous Meningitis
Interventions
DRUG

Trastuzumab

One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg

Trial Locations (10)

14076

François Baclesse Center, Caen

31100

Institut Univesitaire du Cancer de Toulouse, Toulouse

33076

Institut Bergonié, Bordeaux

34298

Institut du Cancer de Montpellier, Montpellier

38700

CHU Grenoble, Grenoble

59020

Oscar Lambret Center, Lille

69373

Léon Bérard Center, Lyon

75248

Institut Curie - Claudius Regaud Hospital, Paris

75651

Pitie Salpetriere Hospital, Paris

92210

Rene Huguenin Hospital, Saint-Cloud

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Centre Leon Berard

OTHER

collaborator

Groupe Hospitalier Pitie-Salpetriere

OTHER

collaborator

Centre Oscar Lambret

OTHER

collaborator

Centre Francois Baclesse

OTHER

collaborator

Institut Bergonié

OTHER

collaborator

University Hospital, Toulouse

OTHER

collaborator

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER

collaborator

University Hospital, Grenoble

OTHER

lead

Institut Curie

OTHER